



THE DATA CAN SUPPORT:

- Bulk antibody screening and lead Ab selection
- Stable cell line development and cell culture process development for CMC
- · Drug release and IND filling

KEY FEATURES OF THE CHEMPARTNER ADCC/CDC ASSAY

- Stable NK92-CD16A cell line as ADCC effector cells or provide repeatable data
- Target cell labeling techniques to ensure detection of target cell-specific cytotoxicity
- Effective strategy to select model cell lines and optimize ADCC/CDC assay for new targets
- Antibody engineering techniques to enhance ADCC/CDC effect
- Established ADCC format including but not limited to CD20, Her2, EGFR, and CD52
- Fc receptor and C1q binding confirmation by Biacore or FACS


CASE STUDY I: ESTABLISH ADCC ASSAY FOR A NEW TARGET XXX


MODEL CELL LINE SELECTION


Cell line	Target protein expression level (FACS MFI)	Fc receptor expression level (FACS MFI)	Selection priority for ADCC assay
293F-XXX	6,769	32	1
OCI-AML-1	2,620	93	2
SK-MEL-28	1,427	56	2
MV-4-11	3,176	1,542	3
HL-60	825	419	3
THP-1	1,213	7,226	4


ASSAY OPTIMIZATION: EFFECT TO TARGET CELL RATIO AND INCUBATION TIME


AB ENGINEERING TO ENHANCE ADCC EFFECT














CASE STUDY II: ESTABLISHED ADCC ASSAY

Success in several targets, including but not limited to:

- CD20
- HER2
- EGFR
- CD52

